Pharma BD Deal Intelligence
A $100M upfront licensing deal that gave Novartis access to Voyager's gene therapy pipeline in Huntington's disease and spinal muscular atrophy, with total deal value reaching $1.3B on milestones. The heavy back-loading toward unproven preclinical programs left Novartis's actual near-term commitment modest relative to the announced figure.
Voyager Therapeutics enters capsid license agreement and strategic collaboration with Novartis to advance novel gene therapies worth up to $1.3B.
Novartis paid $100 million upfront for access to Voyager's gene therapies for Huntington's disease and SMA.
Partnered Novartis programs for HD, SMA and an undisclosed target continue to advance.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novartis paid $100M upfront for access to Voyager's gene therapy programs targeting Huntington's disease and spinal muscular atrophy.
3K US cases/yr · $5.0B Global HD + SMA Gene Therapy (2030E)
TRACER AAV capsids for CNS gene therapy. Five programs: HD, SMA, plus 3 undisclosed rare neurologic targets. Next-gen capsids designed for efficient brain transduction at lower doses.
SMA: Zolgensma (Novartis) approved. HD: no approved gene therapies. Novel capsids aim to reduce dose and improve safety vs conventional AAV.
Novartis paid $100M upfront for gene therapy programs targeting Huntington and SMA.
Per Voyager's FY2025 results (Mar 9, 2026), the partnered Novartis programs for Huntington's disease, SMA and an undisclosed target continue to advance. No material milestone disclosed specifically under the Novartis HD/SMA collaboration as of this report.
Gene therapy candidates in preclinical development. Novel capsid delivery technology.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Voyager Therapeutics Inc. (this deal) | 2024 | $1.3B | 60 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Gene Therapy deals